Genelux Corporation
Organization details
- Legal name
- Genelux Corporation
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Westlake Village
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GNLX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001231457
Board of directors
-
Gabe Woodward · DirectorSince 2023
-
James L. Tyree · DirectorSince 2023
-
John Thomas · DirectorSince 2023
-
John W. Smither · DirectorSince 2023
-
Mary Mirabelli · DirectorSince 2023
-
Thomas Zindrick · Director · President and CEOSince 2023
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-91% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Board connections
1 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Attovia Therapeutics Inc. Same sectorvia John W. Smither
-
NewAmsterdam Pharma Company N.V. Same sectorvia John W. Smither
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $377,213
- 28 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Cappello Joseph Officer (Chief Technical Officer) | Open-market sale | −668 | $2.04 | $1,363 |
| Nov 3, 2026 | Yu Yong Officer (Chief Scientific Officer) | Open-market sale | −668 | $2.01 | $1,344 |
| Nov 3, 2026 | Thomas Zindrick Officer (President and CEO) | Open-market sale | −3,089 | $2.05 | $6,317 |
| Aug 31, 2026 | Cappello Joseph Officer (Chief Technical Officer) | Open-market sale | −10,257 | $2.74 | $28,104 |
| Aug 31, 2026 | Yu Yong Officer (Chief Scientific Officer) | Open-market sale | −9,683 | $2.75 | $26,628 |
| Aug 31, 2026 | Thomas Zindrick Officer (President and CEO) | Open-market sale | −34,463 | $2.67 | $92,016 |
| Aug 4, 2026 | Cappello Joseph Officer (Chief Technical Officer) | Open-market sale | −653 | $2.95 | $1,926 |
| Aug 4, 2026 | Thomas Zindrick Officer (President and CEO) | Open-market sale | −3,023 | $2.95 | $8,918 |
| Aug 4, 2026 | Yu Yong Officer (Chief Scientific Officer) | Open-market sale | −653 | $2.94 | $1,920 |
| Jul 1, 2026 | John W. Smither Director | Open-market sale | −12,000 | $2.91 | $34,920 |
| Jun 16, 2026 | Groen Eric Officer (General Counsel) | Grant or award | +233,957 | — | — |
| Jun 16, 2026 | Pulisic Matthew Officer (Chief Financial Officer) | Grant or award | +278,906 | — | — |
| Jun 16, 2026 | Cappello Joseph Officer (Chief Technical Officer) | Grant or award | +174,841 | — | — |
| Jun 16, 2026 | James L. Tyree Director | Grant or award | +28,409 | — | — |
| Jun 16, 2026 | Thomas Zindrick Officer (President and CEO) | Grant or award | +730,601 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Genelux Corporation
Who is the CEO of Genelux Corporation?
Thomas Zindrick has been Genelux Corporation's President and CEO since January 2023.
How many directors are on Genelux Corporation's board?
Genelux Corporation's board has 6 directors: Gabe Woodward, James L. Tyree, John Thomas, John W. Smither, Mary Mirabelli and Thomas Zindrick.
Are Genelux Corporation insiders buying or selling shares?
Over the last 12 months, Genelux Corporation insiders made no open-market purchases and sold $377,213 of shares in 28 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="genelux-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.